News & Events

Investors

E-mail Alerts

Nov 10, 2020

Viking Therapeutics to Present at Stifel Healthcare Conference 2020

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Oct 28, 2020

Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Oct 21, 2020

Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020

Conference Call Scheduled for Wednesday, October 28 at 4:30 p.m. Eastern Time

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today...
Sep 9, 2020

Viking Therapeutics Announces Initiation of Phase 1 Clinical Trial of VK0214

First-in-human clinical trial of novel, selective thyroid receptor ß agonist for X-ALD

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Sep 2, 2020

Viking Therapeutics to Participate in Upcoming Investor Conferences

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...